SCM
VTGN icon

Soleus Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

Soleus Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-550,000
Closed -$1.95M – 117
2025
Q3 		$1.95M Buy
+550,000
New +$1.64M 0.1% 75
2022
Q3 		– Sell
-27,500
Closed -$726K – 91
2022
Q2 		$726K Buy
+27,500
New +$971K 0.11% 71

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Soleus Capital Management's VTGN Position: Q4 2025 in Review

Soleus Capital Management sold out of VistaGen Therapeutics (VTGN) in Q4 2025, closing a stake of 550,000 shares — an estimated $1.95M sold.

Soleus Capital Management first reported a position in VTGN in Q2 2022 and held it in 2 quarters. The position peaked at $1.95M in Q3 2025. 55 funds tracked by Wall St. Rank hold VTGN as of Q4 2025.

  • Soleus Capital Management reported no remaining VistaGen Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Soleus Capital Management sold 550,000 VistaGen Therapeutics shares in Q4 2025, an estimated $1.95M.
  • Soleus Capital Management first reported a position in VistaGen Therapeutics in Q2 2022 and held it in 2 quarters.
  • Soleus Capital Management's VistaGen Therapeutics position peaked at $1.95M in Q3 2025.
  • 55 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2025.

Based on Soleus Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.